Literature DB >> 25384395

Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.

G Jeudy1, S Dalac-Rat2, B Bonniaud2, A Hervieu2, T Petrella3, E Collet2, P Vabres2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25384395     DOI： 10.1111/bjd.13522

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  10 in total

Review 1.  Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors:  Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

2.  Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.

Authors:  Natalia Maximova; Alessandra Maestro; Davide Zanon; Annalisa Marcuzzi
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

Review 3.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

5.  Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib.

Authors:  Camille Pinard; Claire Mignard; Agnès Samain; Anne-Bénédicte Duval-Modeste; Pascal Joly
Journal:  JAAD Case Rep       Date:  2017-11-06

Review 6.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

Review 7.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

8.  Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.

Authors:  Ahmed I Tahseen; Neel B Patel
Journal:  JAAD Case Rep       Date:  2018-10-10

9.  Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!

Authors:  Camille Luherne; Anne-Sophie Darrigade; Caroline Dutriaux; Sorilla Prey; Brigitte Milpied
Journal:  JAAD Case Rep       Date:  2019-04-28

Review 10.  Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.

Authors:  Adarsh Vennepureddy; Nishitha Thumallapally; Vijeyaluxmy Motilal Nehru; Jean-Paul Atallah; Terenig Terjanian
Journal:  J Clin Med Res       Date:  2015-12-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.